Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1

Authors: Xiao-nan Chen, Ke-feng Wang, Zhen-qun Xu, Shi-jie Li, Qiang Liu, Dong-hui Fu, Xia Wang, Bin Wu

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

MiR-133b is a muscle-specific microRNA; it has a role in the formation of cardiocytes and the expression of myocardium ion channels by regulating target genes. Many human malignant tumors demonstrate a low expression of miR-133b, as noted in colorectal, lung, esophagus and bladder cancers, but the role of miR-133b in bladder cancer is unknown.

Methods

The expression of miR-133b in clinical bladder cancer specimens and adjacent normal tissues was confirmed by stem-loop RT-PCR. We also analyzed the relationship between miR-133b expression and clinicopathological factors of bladder cancer. Bcl-w and Akt1 protein expression in 41 bladder cancer specimens and adjacent normal tissues was detected by Western blot. After transfection of miR-133b mimics or inhibitor into a T24 human bladder cancer cell line, Bcl-w and Akt1 protein and mRNA expression were examined by Western blot and RT-PCR, respectively. The effect of miR-133b on T24 cell proliferation and apoptosis was measured by CCK-8 tests and flow cytometry, respectively.

Results

The expression of miR-133b in bladder cancer tissues from 41 patients was significantly down-regulated (P < 0.01); low expression of miR-133b was strongly associated with high-grade bladder cancer (P < 0.01). Bcl-w and Akt1 proteins were significantly overexpressed in bladder cancer tissues versus adjacent normal tissues (P < 0.01 for both). The expression of Akt1 and Bcl-w proteins and Akt1 mRNA, in T24 cells was significantly down-regulated or up-regulated after transfection of miR-133b mimics or inhibitor, respectively; however, there was no significant difference in Bcl-w mRNA expression. Transfection of HEK-293 T cells with miR-133b significantly suppressed a luciferase-reporter containing the Bcl-w or Akt 1 3′-untranslated regions. MiR-133b mimics significantly inhibited T24 cell proliferation, as well as increased T24 cell apoptosis (P < 0.05 and P < 0.01, respectively) while the miR-133b inhibitor increased and decreased these, respectively (P < 0.05 for both).

Conclusions

MiR-133b may play a very important role in the proliferation and apoptosis of T24 cells by regulating the expression of Bcl-w and Akt1.
Appendix
Available only for authorised users
Literature
1.
2.
Schickel R, Boyerinas B, Park SM, Peter ME: MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008, 27 (45): 5959-5974. 10.1038/onc.2008.274.CrossRefPubMed
3.
Zhang B, Pan X, Cobb GP, Anderson TA: MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007, 302 (1): 1-12. 10.1016/j.ydbio.2006.08.028.CrossRefPubMed
4.
Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H: Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev. 2010, 11 (4): 905-911.PubMed
5.
Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC: Distinct MicroRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009, 69 (21): 8472-8481. 10.1158/0008-5472.CAN-09-0744.CrossRefPubMedCentralPubMed
6.
Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007, 25 (5): 387-392. 10.1016/j.urolonc.2007.01.019.CrossRefPubMed
7.
Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, García-Foncillas J: Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006, 5: 29-10.1186/1476-4598-5-29.CrossRefPubMedCentralPubMed
8.
Goldsmith KC, Lestini BJ, Gross M, Ip L, Bhumbla A, Zhang X, Zhao H, Liu X, Hogarty MD: BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ. 2010, 17 (5): 872-882. 10.1038/cdd.2009.171.CrossRefPubMedCentralPubMed
9.
Vogler M, Dinsdale D, Dyer MJ, Cohen GM: Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009, 16 (3): 360-367. 10.1038/cdd.2008.137.CrossRefPubMed
10.
O’Reilly LA, Print C, Hausmann G, Moriishi K, Cory S, Huang DC, Strasser A: Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ. 2001, 8 (5): 486-494. 10.1038/sj.cdd.4400835.CrossRefPubMed
11.
Pritchard DM, Print C, O’Reilly L, Adams JM, Potten CS, Hickman JA: Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene. 2000, 19 (34): 3955-3959. 10.1038/sj.onc.1203729.CrossRefPubMed
12.
13.
Courchesne SL, Karch C, Pazyra-Murphy MF, Segal RA: Sensory neuropathy due to loss of Bcl-w. J Neurosci. 2011, 31 (5): 1624-1634. 10.1523/JNEUROSCI.3347-10.2011.CrossRefPubMedCentralPubMed
14.
Kumar A, Rajendran V, Sethumadhavan R, Purohit R: AKT kinase pathway: a leading target in cancer research. ScientificWorldJournal. 2013, 2013: 756134-PubMedCentralPubMed
15.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005, 4 (12): 988-1004. 10.1038/nrd1902.CrossRefPubMed
16.
Kumar A, Purohit R: Cancer associated E17K mutation causes rapid conformational drift in AKT1 Pleckstrin Homology (PH) domain. PLoS One. 2013, 8 (5): e64364-10.1371/journal.pone.0064364.CrossRefPubMedCentralPubMed
17.
Kim MO, Lee MH, Oi N, Kim SH, Bae KB, Huang Z, Kim DJ, Reddy K, Lee SY, Park SJ, Kim JY, Xie H, Kundu JK, Ryoo ZY, Bode AM, Surh YJ, Dong Z: [6]-Shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2.Carcinogenesis 2013 . Epub ahead of print.,
18.
Gai L, Cai N, Wang L, Xu X, Kong X: Ursolic acid induces apoptosis via Akt/NF-κB signaling suppression in T24 human bladder cancer cells. Mol Med Rep. 2013, 7 (5): 1673-1677.PubMed
19.
Juanpere N, Agell L, Lorenzo M, De Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S: Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum Pathol. 2012, 43 (10): 1573-1582. 10.1016/j.humpath.2011.10.026.CrossRefPubMed
20.
21.
Parasramka MA, Ho E, Williams DE, Dashwood RH: MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol Carcinog. 2012, 51 (3): 213-230. 10.1002/mc.20822.CrossRefPubMedCentralPubMed
22.
Hummel R, Maurer J, Haier J: MicroRNAs in brain tumors: a new diagnostic and therapeutic perspective?. Mol Neurobiol. 2011, 44 (3): 223-234. 10.1007/s12035-011-8197-x.CrossRefPubMed
23.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116 (2): 281-297. 10.1016/S0092-8674(04)00045-5.CrossRefPubMed
24.
Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6 (4): 259-269. 10.1038/nrc1840.CrossRefPubMed
25.
Ambros V: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003, 113 (6): 673-676. 10.1016/S0092-8674(03)00428-8.CrossRefPubMed
26.
Carlsson J, Davidsson S, Helenius G, Karlsson M, Lubovac Z, Andrén O, Olsson B, Klinga-Levan K: A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int. 2011, 11 (1): 14-10.1186/1475-2867-11-14.CrossRefPubMedCentralPubMed
27.
Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D, Summerhayes IC: A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol. 2010, 28 (1): 39-48. 10.1016/j.urolonc.2008.06.006.CrossRefPubMed
28.
Baffa R, Fassan M, Volinia S, O’Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A: MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009, 219 (2): 214-221. 10.1002/path.2586.CrossRefPubMed
29.
Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Månsson W, Rovira C, Höglund M: MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 2009, 124 (9): 2236-2242. 10.1002/ijc.24183.CrossRefPubMed
30.
Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H: MiR-145, miR-133a and miR-133b: tumor-suppr-Essive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010, 127 (12): 2804-2814. 10.1002/ijc.25284.CrossRefPubMed
31.
Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, Nakagawa M: MiR-145 and mrR-133a function as tumor suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010, 102 (5): 883-891. 10.1038/sj.bjc.6605570.CrossRefPubMedCentralPubMed
32.
Hu G, Chen D, Li X, Yang K, Wang H, Wu W: miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther. 2010, 10 (2): 190-197. 10.4161/cbt.10.2.12186.CrossRefPubMed
33.
Lee HW, Lee SS, Lee SJ, Um HD: Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res. 2003, 63 (5): 1093-1100.PubMed
34.
Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS, Choi KM, Um HD: Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res. 2006, 66 (10): 4991-4995. 10.1158/0008-5472.CAN-05-4254.CrossRefPubMed
35.
Guo WJ, Wang AY, Gao C: Apoptosis and expression of apoptosis-related proteins Bcl-2, Bcl-xL and Bcl-w in human colon adenocarcinoma. World Chin J Degestology. 2009, 17 (25): 2589-2594.
36.
Sun XF, Sun ZY, Pan B, Li L, Shen W: Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer. Mol Biol Rep. 2012, 39 (5): 5631-5636. 10.1007/s11033-011-1369-y.CrossRefPubMed
37.
Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA: AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene. 2010, 29 (1): 150-155. 10.1038/onc.2009.315.CrossRefPubMed
38.
Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP: microRNA 133B targets prosurvival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun. 2009, 388 (3): 483-489. 10.1016/j.bbrc.2009.07.143.CrossRefPubMedCentralPubMed
39.
Wei Y, Hegarty JP, Berg A, Chen X, West G, Kelly AA, Wang Y, Poritz LS, Koltun WA, Lin Z: NKX2-3 transcriptional regulation of endothelin-1 and VEGF signaling in human intestinal microvascular endothelial cells. PLoS One. 2011, 6 (5): e20454-10.1371/journal.pone.0020154.CrossRef
40.
Shen L, Li J, Xu L, Ma J, Li H, Xiao X, Zhao J, Fang L: miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med. 2012, 3 (3): 475-480.PubMedCentralPubMed
Metadata
Title
MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1
Authors
Xiao-nan Chen
Ke-feng Wang
Zhen-qun Xu
Shi-jie Li
Qiang Liu
Dong-hui Fu
Xia Wang
Bin Wu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-014-0070-3

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue

Primary research

Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases

Primary research

High threshold of β1 integrin inhibition required to block collagen I-induced membrane type-1 matrix metalloproteinase (MT1-MMP) activation of matrix metalloproteinase 2 (MMP-2)

Primary research

Induction of H2AX phosphorylation in tumor cells by gossypol acetic acid is mediated by phosphatidylinositol 3-kinase (PI3K) family

Primary research

Association between genetic polymorphisms in AURKA (rs2273535 and rs1047972) and breast cancer risk: a meta-analysis involving 37,221 subjects

Primary research

Comparative secretomic and N-glycoproteomic profiling in human MCF-7 breast cancer and HMEpC normal epithelial cell lines using a gel-based strategy

Primary research

CD28-, CD45RAnull/dim and natural killer-like CD8+ T cells are increased in peripheral blood of women with low-grade cervical lesions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits